Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Certara
(NASDAQ:CERT)
Intraday
$16.16
0
[0.00%]
After-Hours
$16.16
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$16.16
0
[0.00%]
At close: Apr 22
$16.16
0
[0.00%]
PreMarket: 4:20PM EDT
Get Report
Watch
Q1 2024 Earnings in 14 days from now on Tue May 7th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Certara Stock (NASDAQ:CERT)
Certara Stock (NASDAQ: CERT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
Certara shares are trading higher after KeyBanc upgraded the stock from Sector Weight to Overweight.
Benzinga Newsdesk
-
Apr 10, 2024, 7:13AM
Keybanc Upgrades Certara to Overweight, Announces $23 Price Target
Benzinga Newsdesk
-
Apr 10, 2024, 4:38AM
Thursday, April 04, 2024
Decoding 4 Analyst Evaluations For Certara
Benzinga Insights
-
Apr 4, 2024, 8:01AM
JMP Securities Initiates Coverage On Certara with Market Perform Rating
Benzinga Newsdesk
-
Apr 4, 2024, 4:54AM
Friday, March 01, 2024
Certara shares are trading higher after the company reported better-than-expected Q4 financial results.
Benzinga Newsdesk
-
Mar 1, 2024, 1:10PM
UBS Maintains Neutral on Certara, Raises Price Target to $20
Benzinga Newsdesk
-
Mar 1, 2024, 11:38AM
Analyst Scoreboard: 4 Ratings For Certara
Benzinga Insights
-
Mar 1, 2024, 11:00AM
Jefferies Maintains Hold on Certara, Raises Price Target to $15.5
Benzinga Newsdesk
-
Mar 1, 2024, 7:23AM
Thursday, February 29, 2024
Certara Sees 2024 Adj. EPS $0.41-$0.46 vs $0.48 Est., Revenue $385M-$400M vs $363.95M Est.
Benzinga Newsdesk
-
Feb 29, 2024, 4:12PM
Certara Q4 2023 Adj EPS $0.090 Misses $0.110 Estimate, Sales $88M Beat $86.596M Estimate
Benzinga Newsdesk
-
Feb 29, 2024, 4:11PM
Earnings Scheduled For February 29, 2024
Benzinga Insights
-
Feb 29, 2024, 5:15AM
Monday, February 26, 2024
Leerink Partners Initiates Coverage On Certara with Market Perform Rating, Announces Price Target of $19
Benzinga Newsdesk
-
Feb 26, 2024, 8:36AM
Tuesday, January 30, 2024
Tax Season Is Here: Meet The New Federal Program That Can Eat Away At Tax Preparation Companies
Natan Ponieman
-
Jan 30, 2024, 2:31PM
Thursday, January 25, 2024
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $18
Benzinga Newsdesk
-
Jan 25, 2024, 9:43AM
Wednesday, December 13, 2023
Certara Acquires Applied BioMath; No Terms Disclosed
Benzinga Newsdesk
-
Dec 13, 2023, 4:32PM
Thursday, December 07, 2023
UBS Initiates Coverage On Certara with Neutral Rating, Announces Price Target of $17
Benzinga Newsdesk
-
Dec 7, 2023, 6:09AM
Tuesday, December 05, 2023
Keybanc Initiates Coverage On Certara with Sector Weight Rating
Benzinga Newsdesk
-
Dec 5, 2023, 6:18AM
Tuesday, November 21, 2023
Certara Introduces Simcyp Biopharmaceutics Software To Increase Efficiency Of Novel And Generic Drug Formulation & Development
Benzinga Newsdesk
-
Nov 21, 2023, 4:33PM
Wednesday, November 08, 2023
Certara Reiterates FY23 Adj. EPS $0.44-$0.48 Vs $0.45 Est.; Revenue $345M-$360M Vs $352.9M Est.
Benzinga Newsdesk
-
Nov 8, 2023, 5:13PM
Certara Q3 2023 Adj. EPS $0.11 Inline With Estimate, Revenue $85.6M Misses $86.245M Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 4:44PM
Recap: Certara Q3 Earnings
Benzinga Insights
-
Nov 8, 2023, 4:15PM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Wednesday, October 11, 2023
The Latest Analyst Ratings for Certara
Benzinga Insights
-
Oct 11, 2023, 11:00AM
Stephens & Co. Reiterates Overweight on Certara, Maintains $20 Price Target
Benzinga Newsdesk
-
Oct 11, 2023, 8:23AM
Tuesday, September 19, 2023
Certara Announces 300th Regulatory Submission Milestone Using Its Technology-Enabled Services And Software
Benzinga Newsdesk
-
Sep 19, 2023, 8:15AM
Tuesday, August 29, 2023
Certara Simcyp Group Awarded Two New Grants From U.S. FDA; Amount Not Disclosed
Benzinga Newsdesk
-
Aug 29, 2023, 8:27AM
Tuesday, August 22, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
Benzinga Insights
-
Aug 22, 2023, 11:00AM
Jefferies Downgrades Certara to Hold, Lowers Price Target to $17
Benzinga Newsdesk
-
Aug 22, 2023, 5:18AM
Tuesday, August 15, 2023
B of A Securities Maintains Buy on Certara, Lowers Price Target to $24
Benzinga Newsdesk
-
Aug 15, 2023, 9:22AM
Friday, August 11, 2023
The Latest Analyst Ratings for Certara
Benzinga Insights
-
Aug 11, 2023, 10:00AM
Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $16
Benzinga Newsdesk
-
Aug 11, 2023, 7:15AM
Thursday, August 10, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 11:00AM
Morgan Stanley Maintains Equal-Weight on Certara, Raises Price Target to $235
Benzinga Newsdesk
-
Aug 10, 2023, 10:23AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Aug 10, 2023, 9:06AM
William Blair Downgrades Certara to Market Perform
Benzinga Newsdesk
-
Aug 10, 2023, 8:32AM
Certara shares are trading lower after the company reported worse-than-expected Q2 financial results and issued weak guidance.
Benzinga Newsdesk
-
Aug 10, 2023, 8:26AM
Credit Suisse Maintains Outperform on Certara, Lowers Price Target to $21
Benzinga Newsdesk
-
Aug 10, 2023, 8:01AM
Wednesday, August 09, 2023
Certara Sees FY23 EPS $0.44-$0.48 Vs $0.52 Est.; Revenue $345M-$360M Vs $377.16M Est.
Happy Mohamed
-
Aug 9, 2023, 5:45PM
Certara shares are trading lower after the company reported worse-than-expected Q2 financial results.
Benzinga Newsdesk
-
Aug 9, 2023, 4:29PM
Certara Q2 Adj EPS $0.12 Misses $0.13 Estimate, Sales $90.45M Miss $92.18M Estimate
Benzinga Newsdesk
-
Aug 9, 2023, 4:27PM
Earnings Scheduled For August 9, 2023
Benzinga Insights
-
Aug 9, 2023, 4:54AM
Thursday, July 27, 2023
Morgan Stanley Maintains Equal-Weight on Certara, Raises Price Target to $22
Benzinga Newsdesk
-
Jul 27, 2023, 11:53AM
Monday, May 22, 2023
Looking Into Certara's Return On Capital Employed
Benzinga Insights
-
May 22, 2023, 10:47AM
Tuesday, May 09, 2023
Certara shares are trading lower following Q1 earnings.
Benzinga Newsdesk
-
May 9, 2023, 10:26AM
Monday, May 08, 2023
Certara Q1 EPS $0.12, Inline, Sales $90.30M Miss $90.99M Estimate
Happy Mohamed
-
May 8, 2023, 4:17PM
Earnings Scheduled For May 8, 2023
Benzinga Insights
-
May 8, 2023, 9:03AM
Thursday, April 27, 2023
Certara Customers Received 90% Of U.S. FDA Novel Drug Approvals For 9th Consecutive Year
Happy Mohamed
-
Apr 27, 2023, 8:24AM
Wednesday, April 12, 2023
Analyst Expectations for Certara's Future
Benzinga Insights
-
Apr 12, 2023, 12:00PM
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
Benzinga Insights
-
Apr 12, 2023, 11:00AM
Stephens & Co. Initiates Coverage On Certara with Overweight Rating, Announces Price Target of $28
Benzinga Newsdesk
-
Apr 12, 2023, 5:00AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch